Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirk Chan-Tack

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Hepatology (Baltimore, Md.)|October 24, 2017
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluationKimberly Struble, Kirk Chan-Tack, Karen Qi, et al.
Journal of Virus Eradication|November 9, 2019
Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trialsKimberly Struble, Kirk Chan-Tack, Karen Qi, et al.
Journal of Clinical Pharmacology|September 23, 2022
Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development ProgramKirk Chan-Tack, Mario Sampson, Justin Earp, et al.
Antiviral Research|September 28, 2021
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's EvaluationKirk Chan-Tack, Patrick Harrington, Timothy Bensman, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Hepatology (Baltimore, Md.)|October 24, 2017
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluationKimberly Struble, Kirk Chan-Tack, Karen Qi, et al.
Journal of Virus Eradication|November 9, 2019
Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trialsKimberly Struble, Kirk Chan-Tack, Karen Qi, et al.
Journal of Clinical Pharmacology|September 23, 2022
Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development ProgramKirk Chan-Tack, Mario Sampson, Justin Earp, et al.
Antiviral Research|September 28, 2021
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's EvaluationKirk Chan-Tack, Patrick Harrington, Timothy Bensman, et al.
Pageof 1